Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy.

Shuroug A Alowais Samantha O LukE Bridget KimNada AlsuhebanyMark Zangardi

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

Cardiotoxicity occurred in a minority of patients with HER2-positive MBC receiving trastuzumab-based therapy for more than one year. LVEF reductions to below the institutional lower limit of normal and therapy modifications were uncommon.

Keyphrases

metastatic breast cancer
late onset
early onset
epidermal growth factor receptor
stem cells
replacement therapy